Molecular immunohematology is rapidly being adopted in transfusion medicine. The acceptance will be further hastened when inexpensive high-throughput technologies become widely available for molecular immunohematology applications, such as HLA and blood group typing. Particularly promising approaches are the rapidly evolving next-generation sequencing platforms. The speakers in this session will explain how widely the approaches differ within this technology. This session starts with an example of the current conventional high-throughput approach for HLA donor and patient typing. Once three different concepts of next-generation sequencing are explained, the speakers will review potential applications of next-generation sequencing for HLA and blood groups, while also detailing their current limitations. The session concludes with a panel discussion and the opportunity for attendees to ask questions.